 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
Gastric Cancer
572016
| ErbB1&2 kinase inhibitor |
GlaxoSmithKline |
III |
| Alimta (pemetrexed) |
Multi-targed folate inhibitor |
Eli Lilly |
II |
| AMG 706 |
MKI VEGFR, PDGFR, Kit, RET |
Amgen |
II |
| BCG 9331 |
Antimetabolite.thymidylate synthase inhibitor |
BTG Pic |
I |
| BMS 188797 |
Taxane analog |
Bristol-Myers Squibb |
II |
| Insega |
Anti-gastrin 17 |
Apthon |
III |
| LMB-9 |
Immunotoxin |
IVAX |
II |
| Orathecin (rubitecan) |
Topoisomerase I inhibitor |
SuperGen |
II |
| OSI-7904L |
Thymidylate synthase inhibitor |
OSI |
II |
| Pemtumomab |
Monoclonal antibody |
Roche |
II |
| Prothecan (Peg-camptothecin) |
Pegylated camptothecin |
Enzon |
II |
| R1549 (pemtumomab) |
MoAB |
Hoffman LaRoche |
II |
| Sutent (sunitinib) SU11248 |
TKI VEGF, PDGFR, FLT-3, Kit |
Pfizer Inc. |
GIST Approved 1-26-06 |
| Taxoprexin (docosahexaenoic acid-paclitaxel) |
Taxane |
Protarga |
II |
| Taxotere (docetaxel) |
Taxoid |
Aventis |
II |
| Xorax ( paclitaxel) |
Taxane |
IVAX |
II |
|
|
For more information contact us at clinicaltrials@cancerconsultants.com
 |
 View Drugs in Pipeline By Disease |
 |
|
|
|
 |
|
 |
|
|
Patient Home
Meeting Calendar
